The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal
Should a waiver be issued, there is no legal mechanism that can compel the transfer of certain types of know-how or trade secrets.
Pharmaceuticals
-
Read more: The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of March 2021.
-
Read more: The Ongoing Step Therapy Debate The Ongoing Step Therapy Debate
Senator Lisa Murkowski’s reintroduction of the Safe Step Act has revived the debate over the prudence of step therapy protocols.
-
Read more: Excluding Pregnant People From Clinical Trials Reduces Patient Safety and Autonomy Excluding Pregnant People From Clinical Trials Reduces Patient Safety and Autonomy
The exclusion of pregnant people from clinical trials has led to inequities in health care during pregnancy.
-
Read more: Drone-Enabled Pharmaceutical Delivery: Navigating Regulatory Turbulence Drone-Enabled Pharmaceutical Delivery: Navigating Regulatory Turbulence
Drone-enabled pharmaceutical delivery offers a number of advantages over its low-tech forebears, not least including patient convenience.
-
Read more: Federal Court Halts Implementation of 340B Dispute Resolution Rule Federal Court Halts Implementation of 340B Dispute Resolution Rule
A U.S. District Court recently halted the implementation of a dispute resolution rule for the 340B Drug Pricing Program.
-
Read more: How Supervised Injection Sites Can Help Address the Overdose Crisis How Supervised Injection Sites Can Help Address the Overdose Crisis
To save lives and improve individual and community outcomes, supervised injection sites should be part of the response to the opioid epidemic.
-
Read more: New Rule Might Increase Out-of-Pocket Drug Costs for Patients New Rule Might Increase Out-of-Pocket Drug Costs for Patients
Patients may face increased out-of-pocket drug costs as a result of a rule finalized by the Centers for Medicare & Medicaid Services in July 2020.
-
Read more: The Myth of Psychedelic Exceptionalism The Myth of Psychedelic Exceptionalism
Psychedelic drug reform is not occurring at the expense of other drug reforms. Instead, it paves the way for larger reforms.
-
Read more: Advancing a Public Health-Promoting National Opioid Policy Advancing a Public Health-Promoting National Opioid Policy
An American public health and safety-promoting drug policy agenda grounded in sound science is long overdue.
